1674364-87-4
Chemical Structure
DS-437
- CAS No.: 1674364-87-4
- Formula:C15H23N7O4S
- Molecular Weight:397.45
IUPAC Name: 1-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)thio)ethyl)-3-ethylurea
InChIKey: CACMCLIHCDTJHL-IDTAVKCVSA-N
SMILES: O[C@@H]([C@H]([C@H](N1C=NC2=C(N=CN=C21)N)O3)O)[C@H]3CSCCNC(NCC)=O
Biological Activity: DS-437 is a dual PRMT5/7 inhibitor (IC50s of PRMT5/7=6 μM). DS-437 is selective for PRMT5 and PRMT7 over 29 other human protein-, DNA-, and RNA-methyltransferases. DS-437 is a S-adenosylmethionine (SAM)-competitive inhibitor of PRMT5. DS-437 also inhibits DNMT3A and DNMT3B, with IC50s of 52 and 62 μM, respectively. DS-437 inhibits the methylation of FOXP3[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DS-437 | 99.22% | DS-437 is a dual PRMT5/7 inhibitor (IC50s of PRMT5/7=6 μM). DS-437 is selective for PRMT5 and PRMT7 over 29 other human protein-, DNA-, and RNA-methyltransferases. DS-437 is a S-adenosylmethionine (SAM)-competitive inhibitor of PRMT5. DS-437 also inhibits DNMT3A and DNMT3B, with IC50s of 52 and 62 μM, respectively. DS-437 inhibits the methylation of FOXP3. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.82
HY-162177SARS-CoV-2-IN-78 -
Similarity Score 0.81
HY-137241S-Adenosyl-3-thiopropylamine -
Similarity Score 0.81
HY-19528RSAH (Standard) -
Similarity Score 0.81
HY-19528S2SAH-13C10 -
Similarity Score 0.81
HY-W423489SARS-CoV-2-IN-76 -
Similarity Score 0.79
HY-111592S-(5′-Adenosyl)-L-cysteine -
Similarity Score 0.78
HY-18684SIBA -
Similarity Score 0.77
HY-16938R5'-Methylthioadenosine (Standard) -
Similarity Score 0.77
HY-16938S5'-Methylthioadenosine-13C6 -
Explore the MedChemAI to find more analogs
References
- [1]. Smil D, et al. Discovery of a Dual PRMT5-PRMT7 Inhibitor.ACS Med Chem Lett. 2015 Mar 2;6(4):408-12. [Content Brief]
- [2]. Nagai Y, et al. PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targetedp185erbB2/neu Tumor Immunotherapy.Front Immunol. 2019 Feb 8;10:174. [Content Brief]
